Neurofibromatosis 2
19
2
3
11
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
10.5%
2 terminated out of 19 trials
84.6%
-1.9% vs benchmark
0%
0 trials in Phase 3/4
45%
5 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (19)
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Study of Aspirin in Patients With Vestibular Schwannoma
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Neurofibromatosis (NF) Registry Portal
Vestibular Precision: Physiology & Pathophysiology
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Concentration and Activity of Lapatinib in Vestibular Schwannomas
PTC299 for Treatment of Neurofibromatosis Type 2
Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
Reliability of Functional Outcome Measures in Neurofibromatosis 2
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
NF2 Natural History Consortium